Document is current
Any future updates will be listed below
-
Authors
Hübschmann, Daniel https://orcid.org/0000-0002-6041-7049
Kreutzfeldt, Simon https://orcid.org/0000-0003-3278-4586
Roth, Benjamin https://orcid.org/0009-0004-8941-3086
Glocker, Katrin
Schoop, Janine
Oeser, Lena
Hausmann, Steffen
Koch, Christian
Uhrig, Sebastian https://orcid.org/0000-0002-0068-5957
Hüllein, Jennifer
Hutter, Barbara https://orcid.org/0000-0002-9034-0329
Fröhlich, Martina
Heilig, Christoph E. https://orcid.org/0000-0001-8869-1421
Teleanu, Maria-Veronica
Lipka, Daniel B. https://orcid.org/0000-0001-5081-7869
Kerle, Irina A. https://orcid.org/0000-0002-3650-488X
Baude-Müller, Annika
Beck, Katja
Heining, Christoph
Glimm, Hanno https://orcid.org/0000-0003-4104-1135
Ückert, Frank
Knurr, Alexander
Fröhling, Stefan https://orcid.org/0000-0001-7907-4595
Horak, Peter https://orcid.org/0000-0003-4536-9306
- License Information
-
More Information
Article History
Received: 29 December 2024
Accepted: 17 December 2025
First Online: 19 January 2026
Competing interests
: D.H.: stock: Platomics; S.K.: consulting or advisory board membership: Roche; honoraria: Roche; D.B.L.: honoraria: Illumina, Infectopharm; C.H.: consulting or advisory board membership: Boehringer Ingelheim; honoraria: Roche, Novartis; research funding: Boehringer Ingelheim; S.F.: consulting or advisory board membership: Illumina; travel or accommodation expenses: Illumina; P.H.: consulting or advisory board membership: Platomics; honoraria: Platomics, Roche, Trillium. The remaining authors declare no competing interests.
